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Background: The neural transcription factor SOX11 is present at specific stages during embryo development with a
very restricted expression in adult tissue, indicating precise regulation of transcription. SOX11 is strongly up-regulated in
some malignancies and have a functional role in tumorgenesis. With the aim to explore differences in epigenetic
regulation of SOX11 expression in normal versus neoplastic cells, we investigated methylation and histone modifications
related to the SOX11 promoter and the possibility to induce re-expression using histone deacetylase (HDAC) or EZH2
inhibitors.
Methods: The epigenetic regulation of SOX11 was investigated in distinct non-malignant cell populations (n = 7) and
neoplastic cell-lines (n = 42) of different cellular origins. DNA methylation was assessed using bisulfite sequencing,
methylation-specific melting curve analysis, MethyLight and pyrosequencing. The presence of H3K27me3 was assessed
using ChIP-qPCR. The HDAC inhibitors Vorinostat and trichostatin A were used to induce SOX11 in cell lines with no
endogenous expression.
Results: The SOX11 promoter shows a low degree of methylation and strong enrichment of H3K27me3 in non-malignant
differentiated cells, independent of cellular origin. Cancers of the B-cell lineage are strongly marked by de novo
methylation at the SOX11 promoter in SOX11 non-expressing cells, while solid cancer entities display a more varying
degree of SOX11 promoter methylation. The silencing mark H3K27me3 was generally present at the SOX11 promoter in
non-expressing cells, and an increased enrichment was observed in cancer cells with a low degree of SOX11 methylation
compared to cells with dense methylation. Finally, we demonstrate that the HDAC inhibitors (vorinostat and trichostatin
A) induce SOX11 expression in cancer cells with low levels of SOX11 methylation.
Conclusions: We show that SOX11 is strongly marked by repressive histone marks in non-malignant cells. In contrast,
SOX11 regulation in neoplastic tissues is more complex involving both DNA methylation and histone modifications. The
possibility to re-express SOX11 in non-methylated tissue is of clinical relevance, and was successfully achieved in
cell lines with low levels of SOX11 methylation. In breast cancer patients, methylation of the SOX11 promoter was
shown to correlate with estrogen receptor status, suggesting that SOX11 may be functionally re-expressed during
treatment with HDAC inhibitors in specific patient subgroups.
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During embryonic development, cell-fate decisions and
lineage commitment are regulated by both transcription
factors and epigenetic mechanisms. The SOX protein
family of transcription factors is known to act as import-
ant regulators of embryonic development, cellular fate
determination and differentiation [1,2]. SOX11, a mem-
ber of the SOXC subgroup, plays an important role in
both embryonic and adult neurogenesis, and is proposed
to regulate self-renewal of neuronal progenitor cells [3].
The expression of SOX11 is absent in most adult differ-
entiated tissues, further supporting the role as a stem
cell specific regulator [4]. SOX11 has been shown to be
regulated by epigenetic events in pluripotent embryonic
stem cells and is marked with both activating (H3K4me3)
and repressive (H3K27me3) histone marks [5]. These bi-
valent marks are thought to keep developmentally import-
ant genes silenced, but poised for activation during lineage
commitment [6]. Bivalent histone marks are often modified
during cell differentiation so that only the active or repres-
sive marks remain [7]. In agreement with this, peripheral
B-cells that lack SOX11 have been reported to be strongly
marked by H3K27me3 [8]. Interestingly, it has been shown
that genes marked with H3K27me3 are targets for de novo
methylation in cancer [9]. This is supported by gene
expression analysis of de novo methylated genes that show
lack of expression already in unmethylated non-malignant
tissues [10].
Aberrant regulation of SOX11 has been observed in
several tumors, leading to expression of the protein or
silencing through promoter DNA methylation. Up-
regulation of SOX11 has been reported in malignant gli-
oma [11], medulloblastoma [12], mantle cell lymphoma
(MCL) [13], as well as subsets of Burkitt’s lymphoma
[14], ovarian cancer [15] and breast cancer [16]. Aber-
rant promoter methylation of SOX11 has been reported
in most mature B-cell lymphomas except MCL, which
express SOX11 [13] and where SOX11 has functional
[17] and prognostic [18] roles. Moreover, the presence of
SOX11 promoter methylation has been shown to be sig-
nificantly higher in patients with lymph node metastasis
compared to patients without metastasis in nasopharyn-
geal carcinoma [19]. SOX11 methylation was also used
in a five-gene biomarker panel to detect bladder cancer
at an early stage [20]. Thus, both SOX11 expression and
methylation pattern correlate to clinical behaviour,
which is of major interest in relation to the novel use of
epigenetic drugs, enabling demethylation and/or reex-
pression of silenced genes.
In the present study, we aimed to further investigate the
epigenetic regulation of SOX11 in non-malignant (n = 7)
and neoplastic cell populations (n = 42) to possibly identify
new clinical subgroups with an aberrant regulation and/or
expression of SOX11. We show that non-malignant cellshave a low degree of DNA methylation but that SOX11 is
enriched with H3K27me3. In neoplastic cells, the epigenetic
regulation of SOX11 is more complex. Most B-cell
lymphomas are heavily methylated in the SOX11 promoter
region while solid tumor cells show a more diverse methy-
lation pattern. Furthermore, in breast cancer, we demon-
strate a correlation between SOX11 methylation and
clinical subtype.
As the use of histone deacetylase (HDAC) inhibitors
in the clinic is continuously growing, we evaluated the
effect of epigenetic drugs on SOX11 expression. We
show that SOX11 expression could be induced in cells
with low levels of methylation by HDAC but not EZH2
inhibitors.
Methods
FACS sorting of non-malignant B-cell populations
Pediatric tonsils (n=6) (Lund University Hospital, Lund,
Sweden) were used as the source of normal non-
malignant B-cells and collected under written informed
consent by parents or guardians. The use was ethically
approved by the regional Lund/Malmo committee (Dnr
242/2006). The lymphocyte population was isolated by
Ficoll gradient centrifugation. Viable B-cell populations
were sorted based on CD markers as follows: naïve B-cells
(CD3-, CD19+, IgD+, CD38-), GC B-cells (CD3-, CD19+,
IgD-, CD38+) and memory B-cells (CD3, CD19+, IgD-,
CD27+). FACS analysis of sorted populations confirmed a
purity of >95%.
Cell culture
Forty two cell lines with different tumor origins were
used to study the epigenetic regulation of SOX11. These
included mantle cell lymphoma (n=10), follicular lymph-
oma (n=3), diffuse large B-cell lymphoma (n=2), Burkitt’s
lymphoma (n=4), epithelial ovarian cancer (n=5), breast
cancer (n=8), lung cancer (n=3), glioma cancer (n=5)
and neuroblastoma cell lines (n=2). Two glioma cell
lines were established from patient tissues and approved
by the Local Ethical Board of the University of Lund,
Sweden, serial no. LU307-98. Informed consent was ob-
tained. To protect patient anonymity, tumor samples
were coded to GBM-LU60 and GBM-LU93. All cell lines
were cultured at 37C° in a humidified atmosphere of 5%
CO2. Details about cell culture media and supplier are
shown in Additional file 1.
DNA preparation and bisulfite conversion
DNA was extracted and purified using QIAamp DNA
Mini Kit (Qiagen, Hilden, Germany) followed by quantifica-
tion on NanoDrop (NanoDrop technologies, Wilmington,
DE, USA). All samples were bisulfite treated with EZ DNA
Methylation Kit (Zymo Research, Irvine, CA, USA) accord-
ing to manufacturer’s protocol. Five hundred nanograms of
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samples were eluted in 20 μl buffer.DNA methylation analysis of FACS sorted populations of
non-malignant B-cells
The CpG island adjacent to the SOX11 transcription
start site was PCR amplified with primers specific for bi-
sulfite treated DNA and subcloned into the TOPO-TA
cloning vector as previously described [17]. Sequencing
of individual alleles was made at GATC Biotech (Konstanz,
Germany). The sequencing files were analyzed using BiQ
Analyzer software [21] http://biq-analyzer.bioinf.mpi-inf.
mpg.de/index.php. Sequences with poor conversion rates
(<95%) and identical clones, possibly generated in the PCR
reaction, were removed. Data presentation images and
methylation statistics were generated using the BDPC web
server [22].DNA methylation microarrays of human breast cells
DNA from human mammary fibroblasts, epithelial cells,
and endothelial cells, as well as mesenchymal bone marrow
stem cells (ScienCell Research Laboratories, CA, USA) was
analyzed. Bisulfite conversion of 500 ng genomic DNA was
performed using the EZ DNA Methylation kit (Zymo Re-
search, Orange, CA, USA) following the manufacturer’s
protocol. We hybridized 200 ng in 4 μl to the Infinium
HumanMethylation450K BeadChip array (Illumina, San
Diego, CA). The array includes five CpG sites within the
SOX11 promoter (cg07065111, cp08432727, cg08526991,
cg12312988, cg13667638, see Additional file 2). Bisulfite
conversion and hybridization to arrays were performed
by the SCIBLU facility, Lund, Sweden. Raw intensities
for methylated (M) and unmethylated (U) signal were
extracted from Illumina’s GenomeStudio. Beta-values
were calculated as M/(M+U). Beta-values with detection p-
value > 0.05 or with less than 3 beads for a signal were set
as missing values. For each sample we performed a peak-
based correction of Illumina I and II chemical assays similar
to et al. [23]. For both assays we smoothed the beta values
(Epanechnikov smoothing kernel) to estimate unmethylated
and methylated peaks, respectively; and the unmethylated
peak was moved to 0 and the methylated peak to 1 using
linear scaling, with beta-values in between stretched ac-
cordingly. Beta-values below 0 were set back to 0 and
values above 1 were set to 1.Analysis of the ENCODE project data
ChIP-seq data (H3K27me3 and H3K4me3) from human
mammary epithelial cells were downloaded from the
ENCODE project [24]. The sequence files were visual-
ized with the Integrative Genomics Viewer (IGV).Methylation-specific melting curve analysis (MS-MCA) of
tumor cell-lines
Primers used in MS-MCA amplify all types of epialleles
that later are discriminated during the melting stage of the
analysis, enabling a qualitative description of the sample.
Primers for MS-MCA [25] were designed to amplify a se-
quence 273 bp upstream of SOX11 transcription start site,
containing 28 CpG sites (See Additional file 2). Primers
used were: 5’-TTTTAATTTTTTGTAGAAGGAG-3’ and
5’-CCTTCCAAACTACACACAA-3’. Amplification and
melting analysis was carried out on LightCycler 2.0 (Roche,
Basel, Switzerland) using Fast Start DNA Master SYBR
Green kit (Roche). Profiles of melting curves for fully meth-
ylated and unmethylated sequence was established using
in vitro methylated DNA (IVM, Millipore, Billerica, MA,
USA) and whole genome amplified DNA (WGA), derived
with GenomiPhi V2 DNA amplification kit (GE Healthcare,
Little Chalfont, Buckinghamshire, United Kingdom), re-
spectively. Examples of how MS-MCA results was inter-
preted are shown in Additional file 3.
MethyLight Analysis of tumor cell-lines
MethyLight is a highly sensitive quantitative method ampli-
fying highly methylated alleles. Data is normalized to a ref-
erence sample and presented as percent methylated
reference (PMR). MethyLight analysis [26] of the SOX11
promoter region was performed on Roche LightCycler 480
realtime PCR using Lightcycler 480 Probes Master Kit
(Roche) with primers 5’-GGTAGGAGTTACGAGTCGG
AGAGA-3 and 5’-ACTACGATCGCGACAAAAAAAAC-
3’ and probe 5’-[6FAM]TCGGGTTGTTTCGATCG
[MGBNFQ]-3’ [20]. The assay was validated with
bisulfite-treated DNA from cell lines unmethylated for
SOX11 and non-bisulfite treated genomic DNA (human
genome DNA, Roche). A dilution series of fully methyl-
ated control (in vitro methylated DNA, IVM, Millipore)
were included in each reaction. A separate reaction for re-
petitive sequence ALUC4 [27] was performed on each
sample to control for input DNA. All reactions were done
in duplicate and an average value of the concentration was
used to determine DNA methylation level in each sample.
Percent methylated reference, PMR were calculated ac-
cording to the formula: PMR= (([SOX11sample]/[ALUC
4sample])/([SOX11IVM]/[ALUC4IVM])) x 100.
Pyrosequencing
The 28 CpG sites investigated with MS-MCA were se-
quenced in bisulfite treated samples using the PyroMark
Q24 platform (Qiagen, Hilden, Germany). One set of
amplification primers (fwd primer: 5’-ATGATATTT
TGATAATTAGTTGAG-3’ and rev primer: 5’-[Btn]
CCTTCCAAACTACACACAA-3’) and two sequencing
primers (seq primer 1: 5’-AGAGAGATTTTAATTTTTTG
TAGA-3’, seq primer 2: 5’-AGTAGGAGAGAGGGGTT-3’ )
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final volume of 25 μl containing PCR buffer (Qiagen), 200
μM each of dNTP, 0.4 μM each primer and 1 U of Taq Hot-
StarTaq DNA polymerase (Qiagen). Sequencing was per-
formed using PyroMark Gold Q24 reagents (Qiagen).
Analysis of the results was carried out with the PyroMark
Q24 software (Qiagen). Results from at least two sequen-
cing events were used to calculate the methylation level at
each CpG site. In vitro methylated DNA (IVM, Millipore)
and whole genome amplified DNA (WGA) derived with
GenomiPhi V2 DNA amplification kit (GE Healthcare),
were used as fully methylated and unmethylated control,
respectively.
RNA isolation and Real-Time qPCR assessment of SOX11
SOX11 mRNA expression was investigated using real-
time quantitative PCR. Cells were lysed and cDNA syn-
thesized using iScriptTM Synthesis Kit (BIORAD,
Hercules, CA, USA) according to manufacture in-
structions. Amplified cDNA was analyzed in triplicates
using SsoFastTM EvaGreen® Supermix with Low ROX
(BIO-RAD) with primers specific for either SOX11: 5’-
GGTGGATAAGGATTTGGATTCG-3’ and 5’-GCTCC
GGCGTGCAGTAGT-3’, or for the house-keeping gene
GAPDH: 5’-AGTAGAGGCAGGGATGATG-3’ and 5’-
TGGTATCGTGGAAGGACTC-3’.
Western blot analysis of SOX11 and EZH2
8 x 106 cells were harvested and protein extract prepar-
ation, quantification was performed as previously de-
scribed by Gustavsson et al. [17]. Protein lysate (20 μg)
were run on a NuPAGE 10% Bis-Tris gel (Invitrogen)
and blotted on to a PVDF membrane using the iBLot®
Dry Blotting System (Invitrogen). The membrane was
blocked in 5% Milk/PBS before incubating with primary
antibodies. Protein expression were assessed using the
following antibodies: SOX11 monoclonal antibody [28],
mouse anti GAPDH antibody (G8795, Sigma-Aldrich, St
Louis, MO, USA) and EZH2 monoclonal antibody
(Clone 11/EZH2, BD Transduction Laboratories, Franklin
Lakes, NJ, USA). A HRP-labeled anti mouse antibody
(P0260, DAKO, Glostrup, Denmark) was used for detec-
tion. Proteins were developed using SuperSignal West
Femto Max Sensitivity Substrate (Pierce Biotechnology,
Rockford, IL, USA) and images retrieved using a CCD-
camera (Odyssey FC Imager from LI-COR Biosciences UK
Ltd, Cambridge, England).
Analysis of TCGA data
Level 2 methylation data from breast tumor samples
from the TCGA data portal https://tcga-data.nci.nih.gov/
tcga/ were processed as described for the human breast
cells. Selecting unique female patients resulted in 669 tu-
mors for further analysis. For 661 of the 669 samples,level 3 RNA sequencing data consisting of normalized
gene counts was available. The transformation log2 (nor-
malized gene count + 1) was used to generate gene ex-
pression levels for further analysis. Pearson correlation
between corrected beta values and gene expression levels
were used to investigate association between promoter
methylation and gene expression levels. ER status was
available for 599 of the tumors; 139 were ER-negative
and 460 were ER-positive. Two-sided Wilcoxon tests
were used to test for differences between ER-positive
and ER-negative tumors.
Histone ChIP
Chromatin immunoprecipitation of H3K27me3 and
H3K4me3 bound regions were performed with the
HighCell ChIP kit (Diagenode, Liege, Belgium) according
to the protocol of the manufacturer. Antibodies against
H3K27me3 (ab6002, Abcam, Cambridge, MA, USA) and
rabbit IgG (Diagenode) were used in the ChIP experiments.
Primers targeting the promoter of GAPDH (Diagenode)
and SOX11 (fwd: 5’-GAGAGCTTGGAAGCGGAGA-3’
rev: 5’-AGTCTGGGTCGCTCTCGTC-3’) were used.
Treatment with Trichostatin A, Vorinostat and GSK343
Cells (1x106) were seeded into a 6-well plate and cul-
tured for 24 hours before drug treatment. Each cell line
was treated with 0, 0.5 and 5 μM trichostatin A (Sigma-
Aldrich), 0, 0.5 and 5 μM Vorinostat (Selleck, Houston,
TX, USA) or 0, 10 and 20 μM GSK343 (Sigma-Aldrich ).
For all treatments, DMSO was used as a vehicle control.
After 24 h (Trichostatin A and Vorinostat) or 72 h
(GSK343) of incubation, cells were harvested, protein lysate
prepared and western blot performed as described above.
Results
The aims of the present study were to explore the epigen-
etic regulation of SOX11 in non-malignant and neoplastic
cells of various origins and to assess the possibility to re-
express SOX11 upon treatment with HDAC inhibitors.
Epigenetic profiling of SOX11 in non-malignant cells
The epigenetic regulation of SOX11 in non-malignant
cells has until now been widely unexplored. To assess if
the previously observed SOX11 promoter methylation
and histone modifications in B cell lymphomas are a
consequence of tumorgenesis or merely reflect the epi-
genetic status of the normal counterpart, non-malignant
mature B cells from three differentiation stages, includ-
ing naive, germinal center (GC) and memory B-cells,
were FACS-sorted from tonsils (n=6).
The SOX11 promoter contains four CpG islands,
where the island most proximal to the transcription start
site has been shown to be determinative for SOX11 expres-
sion [17]. Consequently, 28 CpG sites within this CpG
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The fraction of methylated CpGs was calculated over
all sequenced alleles (10-20 per sample) and revealed a
low degree of SOX11 methylation although a trend of
increased methylation during differentiation was observed
(Figure 1B). However, major inter-individual variations were
observed, especially among the GC B cells. Using ChIP-
qPCR, we further observed that the SOX11 promoter
showed a strong enrichment of H3K27me3 in all three B-
cell populations (Figure 1C). As non-malignant reference
tissue for solid tumors, DNA from human mammary fibro-
blasts, epithelial cells, and endothelial cells, as well asFigure 1 Epigenetic profiling of SOX11 in normal cells. (A) The SOX11 pro
islands with analyzed CpG sites marked. (B) Mean SOX11 promoter methyla
Enrichment of repressive H3K27me3, determined by ChIP-qPCR, within the
status of five CpG sites within the SOX11 promoter, measured with Illumina
cell-types. (E) Enrichment of active (H3K4me3) and repressive (H3K27me3)
data was extracted from the ENCODE project.mesenchymal stem cells were analyzed on Illumina 450K
methylation arrays (as part of a larger study). Information
on five CpGs within the SOX11 promoter was available.
Analysis of the mammary cell types revealed that the two
sites closest to the transcription start site were completely
unmethylated while three sites upstream displayed a low
degree of methylation (Figure 1D). Of note, cg12312988 is
not located within a CpG island (see Additional file 2). Fi-
nally, ChIP-seq data (H3K27me3 and H3K4me3) on human
mammary epithelial cells (downloaded from the ENCODE
project [24]) showed strong enrichments of H3K27me3
over H3K4me3 on the SOX11 promoter (Figure 1E).moter 2000 bp upstream of transcription start site contains four CpG
tion within 28 CpG sites close to the transcription start site. (C)
SOX11 promoter in naïve, GC and memory B-cells. (D) Methylation
450 K methylation array, for several types of non-malignant mammary
histone marks in primary human mammary epithelial cells. ChIP-seq
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tumors
To explore the difference between non-malignant refer-
ence tissue and neoplastic cells, we further investigated
the methylation status of SOX11 in 42 cell lines (Table 1)
representing a wide range of human tumors with sub-
groups known to express SOX11, including lymphoid
malignancies (n=19), ovarian cancer (n=5), breast cancer
(n=8), lung cancer (n=3), brain cancers (n=5) and neuro-
blastoma (n=2). To determine DNA methylation by
complementary methods, MethyLight and methylation-
specific melting curve analysis (MS-MCA) were used.
The MethyLight and MS-MCA assays covered 8/28 and
28/28 CpG sites previously investigated in non-malignant
mature B-cells, respectively (see Additional file 2). Overall,
a good agreement between MethyLight and MS-MCA was
observed in our sample set (Figure 2A and B), although cal-
culated PMR values were significantly lower compared to
absolute values derived from bisulfite sequencing of the
same cell lines [17]. In agreement with public data
[8,17,29], we show that SOX11 is de novo methylated in all
Burkitt’s lymphomas, follicular lymphomas and diffuse large
B-cell lymphomas. In mantle cell lymphomas that express
SOX11, the promoter is generally unmethylated (Figure 2A
and B). Solid tumors show a much more diverse methyla-
tion pattern within the SOX11 promoter (Figure 2C and
D), possibly reflecting clinical subtypes with an altered
epigenetic regulation.
Correlation between promoter methylation and SOX11
expression
To explore the correlation between SOX11 promoter
methylation and expression, each cell line was analyzed
by RT-qPCR and western blot. An inverse correlation
was observed between SOX11 promoter methylation and
gene expression for both lymphoid and solid tumor cells





REC-1, GRANTA-519, JEKO-1, SP53, MINO, Z138,
HBL-2, JVM-2, UPN-2, NCEB-1




Burkitt’s lymphoma BJAB, RAJI, DAUDI, RAMOS
Breast cancer JIMT-1, PMC-42, MDA-MB-231, SK-BR-3, T47D,
BT474, BT9549, L56Br-C1
Ovarian cancer OVCAR-3, TOV-112D, ES-2, A2780, A2780-CP7
Lung cancer A549, DMS-114, NCI-H1299
Glioma HS683, LN-18, U87MG, GMB-LU93, GMB-LU60
Neuroblastoma SK-N-SH, KCN69np<0.001, respectively) (Figure 3A and B). SOX11 protein
was detected in 7/8 (88%) MCL cell-lines with an
unmethylated promoter (Figure 3C), while only 6/14 (43%)
solid cancer cell lines with an unmethylated promoter
had detectable levels of the protein (Figure 3D). As ex-
pected, none of the cell lines with a methylated pro-
moter expressed SOX11 mRNA or protein with the
exception of BJAB. Using MS-MCA, we show that BJAB
has a monoallelic methylation of the SOX11 promoter,
explaining the observed co-existence of a methylated
promoter and expression of mRNA/protein (Figure 2A
and Figure 3A and C). Pyrosequencing was further used
to investigate if specific CpG sites are important for
SOX11 silencing in cell lines with low-to-intermediate
methylation (as determined by MS-MCA and Methy-
Light). Data show that even at very low level of overall
methylation, CpGs close to transcription start site are
significantly methylated compared to expressing cell lines
with a completely unmethylated promoter (Additional file 4).
Finally, we demonstrate a correlation between SOX11
methylation, expression and subtypes in primary breast
cancers. Breast cancer methylation data and RNA-seq data
were downloaded from The Cancer Genome Atlas
(TCGA) and show that SOX11 methylation is more abun-
dant in estrogen recptor (ER) positive tumors (n=460)
compared to ER negative tumors (n=139) (Figure 4A) with
a strong anti-correlation between methylation and expres-
sion in each CpG site (Figure 4B and Table 2).
Chromatin immunoprecipitation of H3K27me3 in
neoplastic cells
As discussed above, normal cells have a strong enrichment
of the silencing histone mark H3K27me3 on the promoter
of SOX11 but show a low degree of promoter methylation
(Figure 1). In contrast, many neoplastic cell lines show a
high degree of SOX11 promoter methylation (Figure 3). To
investigate if neoplastic cell lines with a low degree of
methylation depend on H3K27me3 to silence SOX11, cell
lines with a low or high degree of methylation were investi-
gated to determine the enrichment of H3K27me3 at the
SOX11 promoter. The biological variation was significant,
exemplified by the major variation in enrichment of the
positive control, TSH2B. In two cell lines, DMS-114 and
KCN-69n, the positive control showed such low levels of
enrichment that data on SOX11 cannot be interpreted.
GAPDH was used as a negative control and background
levels were set to the largest observed GAPDH value. We
show that H3K27me3 at the SOX11 promoter is enriched
in several cell lines, including JIMT-1, LN-18 and JVM-2.
However, SK-BR-3 and HS683 show a low enrichment
compared to the positive control (TSH2B) and are likely
dependent on other epigenetic regulation than promoter
methylation or H3K27me3 to silence SOX11 (Figure 5A).
For comparison, three methylated cell-lines were analyzed
Figure 2 SOX11 promoter methylation in tumor cell-lines. SOX11 promoter methylation status assessed with MethyLight and MS-MCA. The
methylation levels analyzed by MethyLight are presented as percent methylated reference (PMR). PMR < 1 was considered as unmethylated promoter.
SOX11 promoter methylation was investigated in lymphoma cell lines with (A) MethyLight and (B) MS-MCA. SOX11 promoter methylation was investigated
in solid tumor cell lines with (C) MethyLight and (D) MS-MCA.
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showed low enrichment of H3K27me3 at the SOX11 pro-
moter compared to the positive control, indicating that
methylation of the promoter may correlate to loss of re-
pressive histone marks (Figure 5B).Trichostatin A and Vorinostat induce expression of SOX11
in unmethylated cells
Since the expression of SOX11 was shown to be regulated
by repressive histone marks with or without an additional
layer of methylation, we investigated the potential of two
Figure 3 Correlation between SOX11 promoter methylation and expression. The correlation between DNA methylation and gene expression was
analyzed with RT-qPCR and western blot. In RT-qPCR, CT values >35 were considered below detection limit and corresponding SOX11 levels were
set to zero. (A) MethyLight (x-axis) and melt curve analysis (see filled, grey or open diamonds) showed an inverse correlation between SOX11
mRNA and promoter methylation in lymphoma cell lines. (B) Likewise, inverse correlation between SOX11 mRNA and promoter methylation was
seen for solid cancer cell lines. For clarity, SOX11 positive (western blot) cell line names are shaded. (C) Western blot analysis of SOX11 and
GAPDH in Burkitt’s lymphoma, follicular lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma cell-lines. (D) Western blot analysis
of SOX11 and GAPDH in breast cancer, ovarian cancer, lung cancer, brain cancer and neuroblastoma cell lines.
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tin A (TSA), to re-express SOX11. The demethylating agent
5-aza-2’-deoxycytidine arrest proliferation already at low
concentrations in lymphoid cells, and demethylation could
thus not be assessed. Cell lines with no detectable
levels of endogenous SOX11 with an unmethylated
promoter were treated with 0, 0.5, and 5 μM of TSA
or vorinostat for 24 hours. Both TSA and vorinostat
induced SOX11 expression in SK-BR-3, JIMT-1 and
KCN-69n. TSA was more potent than vorinostat, and
showed protein induction already at 0.5 μM (Figure 6A).
However, none of the drugs was able to induce SOX11 ex-
pression in DMS-114 and JVM-2, the latter in contrast toprevious results [8]. Although some HDAC inhibitors have
been reported to have a demethylating effect [30-32], we
show that SOX11 expression could not be induced in any
of the strongly methylated cell lines assessed, including
RAJI, A2780-CP7 and DOHH-2 (Additional file 5A). Add-
itionally, we demonstrate that EZH2, the enzyme respon-
sible for H3K27 tri-methylation, was down-regulated
upon TSA treatment (Figure 6B). To investigate if down-
regulation of EZH2 is enough to induce expression of
SOX11, the cell-lines were further treated with GSK343,
an EZH2 inhibitor. However, despite EZH2 down-
regulation in the majority of evaluated cell-lines, SOX11
was not re-expressed (Additional file 5B).
Figure 4 Correlation between SOX11 promoter methylation and ER
positive breast cancer. A) SOX11 promoter methylation is
significantly (p < 0.01) enriched in ER positive breast cancer (n = 460)
compared to ER negative breast cancer (n = 139). B) SOX11 gene
expression is significantly (p < 0.01) enriched in ER negative breast
cancer compared to ER positive breast cancer.
Table 2 Correlation between SOX11 promoter
methylation and gene expression in primary breast
cancers






Std gene expression = 2.42.
Nordström et al. BMC Cancer  (2015) 15:273 Page 9 of 13Discussion
In non-malignant cells, epigenetic mechanisms are used
to ensure flexible gene expression during development
but later also permanent silencing of genes in differenti-
ated tissues. Many human neoplasias display an altered
epigenetic pattern, with overexpression or mutations of
histone modifying enzymes and increased promoter
methylation, leading to silencing of tumor suppressors
[33]. These alterations are often reversible and the use of
epigenetic drugs has become an attractive option to re-
program and sensitize cancer cells. During the last dec-
ade, both DNA demethylating agents (azacitidine and
decitabine) and HDAC inhibitors (vorinostat and romi-
depsin) have been approved by FDA for use in myelo-
dysplastic syndromes and cutaneous T-cell lymphoma,
respectively [34-37]. Thus, epigenetic drugs have shown
success in treatment of lymphoproliferative diseases, and
several novel epigenetic drugs are currently in clinical
trials for use in solid cancers.
With the growing interest in using epigenetic therapies
in both hematological and solid malignancies, studies of
novel epigenetically regulated genes are warranted and
will provide (i) basic understanding, (ii) potential to use
information on methylation in biomarker panels and (iii)
opportunity to re-activate tumor suppressor functions or
induce cancer stem cell differentiation [38-40] using
novel epigenetic treatment strategies. We and others
have during recent years shown that SOX11 is a diag-
nostic [13], prognostic [18,41,42], and functional bio-
marker in classical MCL [17], indolent MCL [43,44],
ovarian cancer [15] and astrocytic gliomas [45]. SOX11
protein expression has been shown to correlate to in-
creased and decreased survival in different tumor entities,
emphasizing different function depending on molecular
and cellular context.
Furthermore, initial epigenetic investigations shown
that SOX11, which is a transcription factor normally
expressed in a stage-specific manner during embryo de-
velopment, has a bivalent histone mark (H3K4me3 and
H3K27me3) [5]. Here we explore the relation between
epigenetic regulation in non-malignant cells and neo-
plastic cells of various origin and demonstrate that
non-malignant cells have a low degree of promoter
methylation and are strongly marked by H3K27me3 in
the SOX11 promoter, independent on investigated cell
lineage. Recently, several reports have suggested a
crosstalk between DNA methylation and H3K27me3. It
has been shown that several genes marked with
H3K27me3 undergo de novo methylation in cancer [9].
In the B-cell lineage, Velichutina et al. observed that
several EZH2 target genes involved in cellular growth,
proliferation and differentiation become methylated in
diffuse large B-cell lymphomas [46]. Additionally, Vire
et al. demonstrated a physical interaction between
Figure 5 Enrichment of H3K27me3 within the SOX11 promoter. Histone methylation of lysine 27 on histone 3 (H3K27me3) was assessed using
chromatin immunoprecipitation and RT-qPCR for GAPDH (negative control), TSH2B (positive control) and SOX11. (A) Enrichment of H3K27me3 in
unmethylated cell lines lacking SOX11. (B) Enrichment of H3K27me3 in methylated cell lines lacking SOX11.
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with this, SOX11 has been reported to be strongly
methylated in most B-cell lymphomas [17], in nasopha-
ryngeal carcinomas [19] and in bladder cancer [20].
This prompted us to further investigate the epigenetic
regulation of SOX11 in solid tumors.
Our data show that the pattern of SOX11 methylation
is more diverse within solid tumor types, compared to
within B-cell lymphomas. Within each investigated
tumor entity, SOX11 could be unmethylated with or
without protein expression or show a varying degree of
methylation reflecting a large degree of inter-tumor
heterogeneity. Interestingly, SOX11 methylation corre-
lates to ER positivity in breast cancer patients. The dif-
ference in epigenetic regulation related to breast cancer
hormone status has previously been demonstrated by
Müller et al. who showed difference in HDAC expres-
sion between ER positive and negative tumors [48]. In
contrast to cell lines derived from solid tumors, B cell
lymphoma cell lines show similar methylation pattern
within each subtype of disease.
DNA microarray studies have shown that HDAC in-
hibitors induce selective changes in gene expression only
affecting a small fraction of genes (2-10%) [49-51]. AsSOX11 has shown to have a functional role and prog-
nostic relevance in multiple cancer entities, we further
investigated the potential to re-express SOX11 using epi-
genetic drugs. Using the HDAC inhibitors vorinostat
and TSA, we show that SOX11 could be re-expressed in
three out of five unmethylated cell lines but not in meth-
ylated cell lines, suggesting that promoter methylation
protects the chromatin from being acetylated and the
gene de-methylated and expressed. Furthermore, TSA
and vorinostat treatment was shown to decrease the ex-
pression of EZH2 in cell lines that re-expressed SOX11,
but not in others, further supporting an important role
of EZH2 and H3K27me3 methylation in the mainten-
ance of SOX11 silencing. Interestingly, Tiwari et al. re-
cently demonstrated that SOX4, which share 91%
sequence homology to SOX11 within the DNA binding
domain [52], regulate the expression of EZH2 in mouse
mammary epithelial and breast cancer cells [53]. How-
ever, using the EZH2 inhibitor GSK343, we show that
decreased levels of EZH2 are not enough to re-express
SOX11. Thus, as recently suggested by Helin et al. [54],
H3K27me3 may be a passive mark of un-transcribed
genes, and other epigenetic- or transcription factors may
initiate the regulation. The re-expression using HDAC
Figure 6 TSA and Vorinostat induce SOX11 expression and EZH2 down-regulation in unmethylated cancer cell-lines. Cells were treated with 0,
0.5 and 5 μM TSA or vorinostat for 24 hours followed by detection of SOX11 and EZH2 with western blot. (A) Unmethylated cancer cell lines
JIMT-1, KCN69n and SK-BR-3 expressed SOX11 after treatment while DMS-114 and JVM-2 remained SOX11 negative. (B) JIMT-1 and KCN69n also
showed a clear down-regulation of EZH2 upon treatment with HDAC inhibitors while the other cell lines did not show any change in EZH2 levels
(data not shown).
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to methylation and H3K27me3, also acetylation is im-
portant in the regulation of SOX11. Vorinostat and TSA
inhibit a broad class of HDACs (HDAC1-4, HDAC6-7,
and HDAC9) [55] and further investigations are needed
to clarify which of these that control SOX11 expression.
Although SOX11 was not re-expressed in methylated cell
lines, an interaction between HDACs and CpG binding
proteins has been demonstrated [56] and HDAC inhibi-
tors have been reported to down regulate the expression
of DNA methyl transferases [57].
Conclusions
To assess the relation between epigenetic regulation of
SOX11 in non-malignant tissue, lymphoid and solid ma-
lignancies, we investigated methylation and H3K27me3
enrichment at the SOX11 promoter in populations of
non-malignant B-cells and fibroblast cells compared to
neoplastic cell lines of various origin. In non-malignant
cells, SOX11 is strongly marked by enrichment of
H3K27me3 while tumors in general show promoter
DNA methylation. Of interest, homogeneous methylation
of the SOX11 promoter is more frequently observed in
lymphomas compared to solid tumors. Analysis of
H3K27me3 enrichment in neoplastic cells show that cell
lines with an unmethylated SOX11 promoter are strongly
marked by H3K27me3, while methylated cell lines are asso-
ciated with decreased H3K27me3 enrichment, indicatingco-regulation of polycomb complex and DNA methyltrans-
ferases. We further show that down-regulation of EZH2
alone do not induce SOX11 expression but that clinically
relevant HDAC inhibitors down-regulate EZH2 and induce
SOX11 expression. Thus, H3K27me3 in combination with
histone acetylation play an important role in SOX11 regula-
tion, and emphasize the need to investigate the potential
functional role of SOX11 upon epigenetic treatment and
subsequent re-expression in patients with hematological or
solid malignancies.Additional files
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